198 related articles for article (PubMed ID: 29643323)
21. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
Sarashina A; Friedrich C; Crowe S; Patel S; Graefe-Mody U; Hayashi N; Horie Y
J Diabetes Investig; 2016 Sep; 7(5):744-50. PubMed ID: 27180969
[TBL] [Abstract][Full Text] [Related]
22. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
23. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
[TBL] [Abstract][Full Text] [Related]
24. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
[TBL] [Abstract][Full Text] [Related]
25. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
Umpierrez GE; Cardona S; Chachkhiani D; Fayfman M; Saiyed S; Wang H; Vellanki P; Haw JS; Olson DE; Pasquel FJ; Johnson TM
J Am Med Dir Assoc; 2018 May; 19(5):399-404.e3. PubMed ID: 29289540
[TBL] [Abstract][Full Text] [Related]
26. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Wu W; Li Y; Chen X; Lin D; Xiang S; Shen F; Gu X
Med Sci Monit; 2015 Sep; 21():2678-84. PubMed ID: 26350766
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Araki E; Kawamori R; Inagaki N; Watada H; Hayashi N; Horie Y; Sarashina A; Thiemann S; von Eynatten M; Dugi K; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):364-71. PubMed ID: 23163910
[TBL] [Abstract][Full Text] [Related]
28. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
Pérez-Belmonte LM; Osuna-Sánchez J; Millán-Gómez M; López-Carmona MD; Gómez-Doblas JJ; Cobos-Palacios L; Sanz-Cánovas J; Barbancho MA; Lara JP; Jiménez-Navarro M; Bernal-López MR; Gómez-Huelgas R
Ann Med; 2019; 51(3-4):252-261. PubMed ID: 31037970
[No Abstract] [Full Text] [Related]
29. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.
Vellanki P; Rasouli N; Baldwin D; Alexanian S; Anzola I; Urrutia M; Cardona S; Peng L; Pasquel FJ; Umpierrez GE;
Diabetes Obes Metab; 2019 Apr; 21(4):837-843. PubMed ID: 30456796
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
[TBL] [Abstract][Full Text] [Related]
31. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
32. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
Giorda CB; Cioffi G; Lucci D; Nada E; Ognibeni F; Mancusi C; Latini R; Maggioni AP;
Cardiovasc Drugs Ther; 2019 Oct; 33(5):547-555. PubMed ID: 31418140
[TBL] [Abstract][Full Text] [Related]
33. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
[TBL] [Abstract][Full Text] [Related]
34. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
[TBL] [Abstract][Full Text] [Related]
36. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
37. Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Ihana-Sugiyama N; Yamamoto-Honda R; Sugiyama T; Tsujimoto T; Kakei M; Noda M
Med Sci Monit Basic Res; 2017 Feb; 23():36-44. PubMed ID: 28242866
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
40. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
